Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

NCT07438106 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT07438106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07438106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
January 28, 2026
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer with kras g12d mutation